1.41

11.32% -0.18

Annovis Bio Inc (ANVS)

Überblick Nachrichten Preisverlauf Warum fällt ANVS? Forum Prognose

Schlusskurs vom Vortag:

$1.59

Offen:

$1.54

24-Stunden-Volumen:

275.08K

Relative Volume:

0.58

Marktkapitalisierung:

$27.48M

Einnahmen:

Nettoeinkommen (Verlust:

$-40.94M

KGV:

-0.3672

EPS:

-3.84

Netto-Cashflow:

$-22.97M

1W Leistung:

-23.78%

1M Leistung:

-14.55%

6M Leistung:

-82.42%

1J Leistung:

-87.51%

1-Tages-Spanne:

$1.40

$1.54

1-Wochen-Bereich:

$1.40

$1.74

52-Wochen-Spanne:

$1.40

$20.00

Annovis Bio Inc Stock (ANVS) Company Profile

Firmenname

Annovis Bio Inc

Sektor

Healthcare (1163)

Branche

Biotechnology (678)

Telefon

484-875-3192

Adresse

101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-12-11

Neueste SEC-Einreichungen

ANVS's Discussions on Twitter

Vergleichen Sie ANVS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ANVS Annovis Bio Inc	1.41	27.48M	0	-40.94M	-22.97M	-3.84
VRTX Vertex Pharmaceuticals Inc	484.01	124.29B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.64	66.76B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	590.06	35.99B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	262.16	33.93B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	264.32	28.47B	3.81B	-644.79M	-669.77M	-6.24

Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-10	Herabstufung	D. Boral Capital	Buy → Hold
2024-10-25	Hochstufung	Maxim Group	Hold → Buy
2023-12-29	Eingeleitet	Canaccord Genuity	Buy
2021-07-07	Bestätigt	Maxim Group	Buy

Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten

Apr 02, 2025

Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MSN

Apr 02, 2025

Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com - Investing.com South Africa

Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline - Investing.com India

Mar 31, 2025

Annovis Bio Receives Non-Compliance Notice from NYSE - MSN

Mar 31, 2025

Mar 30, 2025

Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 - MSN

Mar 30, 2025

Mar 27, 2025

Annovis Bio faces NYSE delisting over market cap, equity shortfall By Investing.com - Investing.com South Africa

Mar 27, 2025

Annovis Bio Gets NYSE Noncompliance Notice - MarketScreener

Mar 27, 2025

Annovis Bio Faces NYSE Non-Compliance Notice - TipRanks

Mar 27, 2025

Annovis Bio faces NYSE delisting over market cap, equity shortfall - Investing.com

Mar 27, 2025

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - GlobeNewswire

Mar 27, 2025

NYSE Warning: Annovis Bio Must Submit 45-Day Survival Plan as Market Cap Plunges - Stock Titan

Mar 27, 2025

Mar 26, 2025

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - GlobeNewswire

Mar 26, 2025

Mar 25, 2025

Stocks In Spotlight: ANVS, PTN, AVIR, IRWD, FGEN, ACAD - RTTNews

Mar 25, 2025

Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN

Mar 25, 2025

Agitation in Alzheimer's Disease Market: Analysis - openPR.com

Mar 25, 2025

Annovis Bio Inc. to Present Key Findings at AD/PD™ 2025 Conference in Vienna on Alzheimer's and Parkinson's Treatments - Nasdaq

Mar 25, 2025

Game-Changing Phase 3 Results: Annovis Reveals Dual Breakthrough in Parkinson's and Alzheimer's Treatment - Stock Titan

Mar 25, 2025

Mar 21, 2025